Aurinia Pharmaceuticals Inc. (AUPH) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped AUPH stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: Aurinia Pharmaceuticals Inc. demonstrates strong growth potential due to its consistent earnings beats and promising drug pipeline. Despite supply chain issues and competitive pressures, the company's fundamentals and positive news highlight its momentum. The stock is positioned for above-average returns with upside potential from forthcoming clinical and regulatory outcomes. The saved 1-year distribution is P10 $12, P50 $16.1, and P90 $19.5.
Last analyzed · Model: gpt-4o
Aurinia Pharmaceuticals Inc. Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $12 | Pessimistic plausible scenario |
| P50 | $16.1 | Median scenario |
| P90 | $19.5 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
With multiple positive catalysts, including a consistent earnings beat streak and FDA approvals, there is strong short-term bullish sentiment, moderated by competitive and supply chain concerns.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this AUPH analysis generated?
March 9, 2026.
Is this a guaranteed AUPH prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full AUPH stock analysis · AUPH sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.